Introduction
Histamine release and undesired histamine release reactions during anesthesia and surgery have been the subject of' extensive and persistent research in ~lnesthesiology,'~"' pharmacology,"-I' and clinical iliimunology'~~'H over the last 20 years. This activity stands in marked contrast to the regrettable f'act that the wealth of' consistent data in this field'-lx is not widely appreciated by anesthesiologists in daily practice. Unwanted histamine release reactions appear clinically as pseudoallergic and allergic reactionsI but also as "atypical" disease entities such as significant arrhythmias, hypertension, myocardial inf'arction,'!'~" vomiting and diarrhea,"' and thrombosis." The reactions are caused by the administration of' several drugs during anesthesia"
and by various physical actions, P.R., intubation2 ' and measures of surgical intervention."' 'They occur more frequently than is generally supposed. Using data obtained from prospective clinical trials, the overall incidence of reactions is about 20%-30%, including increased gastric acid secretion.','" Systemic reactions occur in 1 S--5%, and life-threatening reactions occur in 0.1 S--0.5% of patlents.zl Why don't many countries accept the fact that antihistamines should be given to some groups of surgical patients? A language barrier could be at fault. 'l-he first report associating increased plasma histamine concentrations and clinical symptoms after administration of the hypnotics thiopental sodium and propanidid (Epontol@) in routine anesthesia was published in 1970.2" Based on data from a randomized clinical trial, the same group first demonstrated that adverse pseudoallergic reactions could be prevented completely by administering histamine H,-+ H,-receptor antagonists." ' However, since that trial more than 10 years ago,"' this subject has been discussed without definitive resolution, a situation that now has led to an international niulticenter trial."'~"' In this review, the incidence of adverse pseudoallergic and allergic reactions seen during anesthesia and surgery is addressed, as are the pharmacology of' H ,-+ H,-antihistamirles and the current state of' the art regarding the effectiveness of a combined prophylaxis with H ,-+ I-l,-receptor antagonists.
Finally, a decision tree hr-a problem solving strategy leading to recornIiierldatiotls for the use of H ,-+ H,-blockade as a systematic approach to prevent or reduce the severity of such reactions is presented. from drug to drug. In the case of atracurium, these symptoms were cutaneous signs and changes in heart rate (HR) (tachy-and bradycardia) ."' In the case of polygeline (Haemaccel), the symptoms were tachycardia only and hypertension, whereas flush and erythema were observed in only about 30% of individuals.'* In the case of heparin during cardiac surgery, only arrhythmias+' were detected; and histamine release by the Hz-antagonist cimetidine and ranitidine was accompanied by metallic taste, headache, changes in HR and blood pressure (BP); ranitidine always caused a pale face, neck, and chest.:'" The reasons for the different sets of diagnostic predictors are mast cell heterogeneity in their response to different drugs," additional effects of these agents that act as functional or receptor antagonists, 42 the site and type of application of these agents, and other mediators that are released or formed by the released histamine (p.~., bradycardia induced by noradrenaline release).':' In addition to histamine release, these drugs can also cause adverse reactions by other mechanisms (r.g., myocardial depression, ganglionic blockade) and, hence, complicate the accurate diagnosis of the reactions not only by the omission of, but also by the addition of symptoms/signs.40~'2 Therefore, only one test is available at present for the 95%' accurate diagnosis of a histamine release reaction: increased plasma histamine levels.21~zx~40
Histamine Release Reactions, Allergic and Pseudoallergic Reactions: Classification by Pathomechanisms
Histamine release reactions can be divided into three grades of severity.'" Grade I reactions are local (cutaneous) reactions. The clinical symptoms include erythema, urticaria and/or dermal pruritus only. These reactions are not considered as threatening as the other two grades and no intensified observation or treatment is necessary. The plasma histamine concentra-tions are less than or equal to 1 ngiml. (irade II reactions are systemic. 'I'hey include generalized skin reactions plus discomfort, tachy-or bradycardia, other types of arrhythmias, medium hypo-or hypertension, and respiratory distress. These reactions are considered threatening by both the patient and the doctor, and close observation and/or treatment is necessary. Plasma histamine levels are > 1 ng/ml. 'I'he life-threatening reactions are grade III. Symptoms observed include severe hypotension, ventricular fibrillations, cardiac arrest, bronchospasm, or respiratory arrest. 'These reactions are considered life-threatening by the doctor and require emergency treatment. The plasma histamine levels in these patients are > I2 ng/nL2x
Situations during the Perioperative Period Leading to Increased Plasma Histamine Levels and Histamine Release Reactions
Increased plasma histamine concentrations and adverse reactions for which histamine is a necessary, sufficient, or contributing determinant,'<' occur throughout the perioperative period.".i?,".L4 'l'hese increased histamine levels have been demonstrated in disease states of patients before they enter the operating room (OR), e.g., in polytrauma," septic shock,"'," upper gastrointestinal (GI) bleeding,l' intestinal ischemia, i4,tX renal failure," and mastocytosis.2' The adverse reactions have been shown in these clinical situations by several methods, since the conditions were very complex for a single mediator in these disease states: multivariate causality analysis in septic shock,'+" assessment of stress ulceration in polytrauma,2' effect of H,-+ HZ-antagonists on the survival time in intestinal ischemia.48
The measures that occur before surgery and are associated with increased plasma histamine levels include endoscopy'!' and catheter insertion." Lindlar et aL4" examined four groups of patients scheduled for follow-up endoscopy (esophageal varices, duodenal ulcer, duodenal ulcer after selective proximal vagotomy, and nonspecific abdominal pain). The frequency of increased plasma histamine levels was between 19% and 28%, the highest occurrence rate being observed in the group with esophageal varices. The highest plasma histamine concentration was 6 ng/ml. If emergency patients with upper GI bleeding then have a histamine release reaction either due to the endoscopy itself" or to any drugs that may be preoperatively given, their reactions may be more severe than in those patients undergoing elective surgery. In an animal model for this hypothesis, it was shown in dogs following blood loss and isovolemic hemodilution'" that the same histamine release was much less tolerated than in normal, unpretreated animals, and was associated with considerable mortality.
The most dangerous period for histamine release reactions, however, is at anesthesia induction (Table  4) . l.'L1,2R.R1.34.~9,5061
All of the drugs used can cauSe increased plasma histamine levels and also unwanted histamine release reactions including, at the minimum, increased gastric secretion'" and cardiac dysrhythmias"' as the most sensitive responses to histamine. In addition, all other drugs administered for the prevention of surgical complications, such as heparin,:<" protamine, WM and antibiotics such as vancom ycin,"" metronidazole, and cephalosporines,';" can also cause histamine release and adverse reactions. The vast range of' agents causing histamine release and reactions and the relatively high incidence of such events (Table 4) should serve as a warning, since all of these drugs are used routinely. In severely ill patients, even a minor (< 1 ngiml) or medium (l-10 ng/ml) plasma histamine level otherwise well tolerated by a healthy person, in combination with other mechanisms or mediators such as in polytrauma,Z',f" septic shock,'",*" or following bone cement implantation in an elderly patient ,',i can lead to death, as multivariate causality analysis has shown.'*4,"7 Furthermore, the modulation of histamine release through administration of a mixture of drugs at anesthesia inductionzfi must be considered. Thus, drugs which alone release little or no histamine may cause medium or severe reactions in combination with other agents.% Although etomidate rarely releases histamine when given alone, the authors found that when it was given after muscle relaxants, the timing of the adverse reactions suggested that etomidate might itself have caused some histamine release."8 Similar findings were observed after lormetazepam administration was followed by etomidate."" In a randomized trial, 24 patients received either nalbuphine or fentanyl as analgesics during routine anesthesia.M Five of 11 patients had increased plasma histamine levels after fentanyl, and 6 of 13 patients after nalbuphine. However, after induction of anesthesia with alcuronium, flunitrazepam, and thiopental, only 1 patient had increased plasma histamine levels in the fentanyl group, but 6 patients had increased plasma histamine levels in the nalbuphine group (p < 0.05).
Surgical procedures themselves, in phases independent of anesthesiological measures, release histamine,?1.& 1,SO,(ii.(iX In five standard operations (thyroidectomy, lobectomy or pneumectomy, cholecystectomy, anterior colorectal resection, and aorto-femoral bypass operation), increased plasma histamine concentrations were found during one or more defined phases such as body cavity exploration and detachment of adhesions.fix Other surgical interventions producing increased plasma histamine levels include resection of liver segments and the esophagus,"" kidney and liver transplantation," aneurysmal clipping,'" pediatric cardiopulmonary bypass." and bone cement illiplantatioll."'.i' A special situation during surgery in which free histamine is infused via a central catheter directly into the heart and the pulmonal circulation is the administration of erythrocyte concentrates for blood transfusion. Histainine concentrations are high in the "plasma supernatant" of these infusion mixtures, especially toward the end of administration when high pressure is applied to push the residual blood through the stuffed filters (Figure l) .f'x
Pharmacology of Histamine Receptor Antagonists: Pharmacokinetics and Adverse Reactions

Histamine Receptors
Histamine exerts its physiological actions by binding to specific receptors. '~3 Three receptor types for histamine have been found: H,, HLL, and H,. These receptors are defined pharmacologically by the actions of their agonists and antagonists. Histamine via the H, receptors mediates the following biological effects in humans: decrease in atrioventricular node conductance, coronary artery constriction, vasoconstriction (blood vessels > 80 km), vasodilation (blood vessels (H,) , neutrophils, basophils, eosinophils, and monocytes. In the brain, both H, and H, receptors have been found; indeed, mammalian brain has the highest density of H, binding sites of any organ studied.13.74m56
Recently, the H, receptor, which is involved in the feedback control of histamine release from presynaptic sites, has been described." Its presence also has been described in rat brain and lung. However, a Periope7-atiue uses of histamine antagonists: Lorenz et al. function for these receptors has not yet been shown to be involved in anesthesia and surgery. Hence, the remainder of the article focuses only on H, and H, receptor antagonists.
Histamine H, Receptor Antagonists
An exceedingly large number of H, receptor antagonists are available; however, only a few have been used in anesthesia and surgery. This situation is mainly due to their lipophilic properties; since they are insoluble in water, they are not available for IV administration. The authors, therefore, concentrate on those agents most commonly used in different countries: chlorpheniramine, dimetindene, hydroxyzine, clemastine, and promethazine.
Most of these preparations have been available for 20-30 years and few formal pharmacokinetic studies have been performed, especially after IV administration (Table  5) . 13.i8.7'J However, data on blood levels are insufficient to provide information on the rapidity of onset of the protection, effectiveness of this protection against lifethreatening reactions, and duration of this protection. The binding to the histamine receptors and, after signal-transducing, the final biological reaction, are obviously the most important features. These data are available only from two published studies in dogs21,80 (Tuble 6). Against life-threatening reactions with plasma histamine levels comparable to those in human subjects, 1~6~'L'.55 the H,-receptor antagonist is less effective (about one-half as effective) than the combined H,-+ H,-prophylaxis.
The prophylaxis is protective if administered 15 minutes before the substance producing the adverse reaction and also protective after 2 hours. Methylprednisolone, even administered 2 hours before the histamine releaser, was ineffective in the low dose and worse than placebo in the high dose. From Diet7 el al.,"" with pernlission.
All H,-receptor antagonists have many effects in addition to their "specific" antihistaminic property. 13.X1,R2 Some of these effects are beneficial in pseudoallergic and allergic reactions if they attenuate the effects of other mediators such as serotonin and bradykinin.81 However, most of these drugs act on the central nervous system (CNS), with both stimulation and depression being observed.13J* For example, chlorpheniramine produces stimulation and clemastine fumarate often causes drowsiness. Dimetindene elicits only little sedation, as shown by several psychometric tests and electroencephalographic (EEG) analysis.2' Hydroxyzine is a long-acting compound (Table 5 ) with considerable central depressant activity. However, when given with morphine for postoperative pain, hydroxyzine provides better pain relief than does morphine alone.83 Promethazine hydrochloride is the most sedating agent of its groupig and is still often used for its antiemetic affects. It potentiates the action of the narcotics morphine, pethidine, fentanyl, and pentazocine. 84 Some of these H,-receptor antagonist side-effects on the CNS may be judged differently in anesthesiology than in other medical disciplines. Sedation or potentiation of the effects of other drugs may be welcomed. However, these effects should always be considered.
Until now, two commercially available H, receptor antagonists, cimetidine and ranitidine, have been used in the perioperative period. A wealth of pharmacokinetic data is available (Table 5) , but, again, the binding of the compounds to histamine receptors is a more important feature (Table 6 ) than is the pharmacokinetic data based on plasma levels.
H,-receptor antagonists have side effects in addition to their desired actions. However, adverse reactions to these agents are extremely rare and have been observed only after repeated and chronic use, ~.g., agranulocytosis or hypothalamic-pituitary-gonadal dysfunction.x" There are, however, findings that must be considered by the anesthesiologist:
1. Hemodynamic effects: Rapid IV administration of HZ-receptor antagonists should be avoided. It leads to histamine release and, hence, bradycardia, hypotension, and other cardiotoxic effects.3Y This reaction is not seen after slow infusion.6i 2. Drug interaction: Both cimetidine and ranitidine bind to cytochrome P450 but the binding is weaker for ranitidine. This fact can lead to accumulation of drugs that undergo oxidative degradation, e.g., warfarin, diazepam, theophylline, phenytoin, carbama- 
Effectiveness of a Combined Prophylaxis with H,-+ Hz-receptor Antagonists to Prevent Histamine Release Reactions (Pseudoallergic/Allergic Reactions) during the Perioperative Period
A series of randomized clinical trials have demonstrated clearly that histamine release reactions of all degrees and severity are associated with the various phases of the induction of anesthesia, intraoperative measures, or drug delivery. In these trials, the effectiveness of a combined H,-+ H,-premeditation was proven (Table 7) : y4 loo The fn-st of these trials was performed as long ago as 1977.n5 Since then, this premedication has been shown to be totally effective against anaphylactoid adverse drug reactions of at least grade 2 severity (systemic reactions). However, there has been a reluctance to use this strategy despite its documented effectiveness in clinical trials.'" The reason for this reluctance is not completely clear in the same way as is the reluctance to accept the high incidence of histamine release and histamine release reactions (see Introduction). The first argument frequently raised against the use of antihistamine prophylaxis is that many mediators other than histamine are released from mast cells and basophils. Thus, antihistamine prophylaxis would be expected to be effective only against reactions mediated by histamine.
This line of reasoning is not sustained by clinical experience in which it is documented that the incidence and severity of reactions are greatly reduced even in situations where histamine is not the predominant causal factor."1."7.10" However, in vitro studies have shown that antihistamines in low concentrations are able to inhibit histamine release from mast cells and to protect rat erythrocytes against osmotic shock, probably by stabilizing the cell membranes. ")' The combination of H,-+ H,-receptor antagonists led to a synergistic enhancement of the inhibition.
These findings have been supported by animal studies in uizw. 21~xo In Tublr 6, the reduction in histamine release is up to 80%. In a controlled clinical trial investigating reactions to atracurium, similar findings were first reported for the clinical situation.,"' In the placebo group, 65% of patients responded to atracurium with a measurable clinical syndrome, a histamine release reaction. 'I'hese reactions were reduced to 15% by the use of H,-+ HZ-receptor antagonists.
More histamine release without clinical symptoms was observed in the H,-+ HZ-group, but the extent of the histamine release was markedly reduced. Since histamine release is involved in the process of liberating or forming other mediators,lCP1 inhibition of histamine release also prevents the release of other mast cell-derived mediators. All of these findings provide a rationale for the use of H,-+ H,-receptor antagonists, even in situations where histamine is not the predominant mediator involved in the reaction (such as in gelatine plasma substitutes and morphine)"' but also in nonanaphylactic reactions, or even after complement activation by radiographic contrast media :+(1.97-W The second argument frequently proposed is that this premeditation is not strong enough for lifethreatening reactions. This speculation was clearly shown to be False with data from a number of animal experiments (Tuble 6) .",80 It was, however, also shown to be false in a large prospective study on chemonucleolysis by chymopapain in 3 1,585 patients (Table   7) . 100 
Rationale for a Combined Prophylaxis with H,-and Hz-receptor Antagonists in Anesthesia and Surgery
In all epidemiological and prospective studies reported (for individual data see refs. 5,9,10,21,28, 40,103,104) , life-threatening adverse reactions (grade 3) in which histamine release is causally involved"' occur in 0.1%0.5% of all patients undergoing general anesthesia and surgery. This incidence comprises approximately 15,000 patients per year in West Germany,5s but similar data have been reported for the United Kingdom. L03.104 Data from the Sheffield-based National Adverse Anesthetic Reactions Advisory Service (NAARAS) in the U.K. suggest "something between 5,000 and 10,000 clinically severe reactions each year in every European country."'O" These incidences of adverse reactions are in the same order of magnitude as perioperative thromboembolism, clinically severe bleeding from stress ulceration, and sepsis, all of which have led to prophylactic measures in a substantial proportion of surgical patients.40J0" However, cardiovascular instability observed in medium (systemic grade 2) reactions, which occur with an incidence of between 1-5%,21.28 are also undesirable and should be thoroughly considered.21 More often than supposed, anesthetists treat with fluids, vasopressors, atropine, and other measures in cardiovascular reactions which, after plasma histamine analysis, are shown to be histamine release reactions.40 Even minor increases in plasma histamine levels, in combination with other mediators, can increase morbidity and mortality, as shown for po1ytrauma,45.47 septic shock,44 after administration of radio contrast media,gl or after administration of chymopapain.37 Thus, both histamine release and the adverse reactions should be prevented. What approaches can be taken?
The first step could be discarding all drugs known to release histamine. Some drugs have been removed from the market (propanidid, Althesinm). However, the number of drugs involved is so large that this option is not a viable solution.
The second step could be product improvement so that less histamine release occurs. This option was chosen for the plasma substitute polygeline.j5 The original product was produced with a great excess of hexamethylene diisocyanate and caused severe reactions. The new formulation of purified polygeline (Haemaccel-35@) is produced with only a slight excess of hexamethylene diisocyanate over the stochiometric ratios and causes fewer, less severe reactions.
The third step is to discard histamine-releasing solvents. The reactions are not always caused by the drug itself, often solvents such as Cremophor El@ are to blame. For example, propofol (Diprivan@) is now formulated with the IV fat emulsion Intralipid@ instead of' Cremophor El@, and the incidence of severe reactions is decreased. Again, however, this option is not viable in all cases.
The fourth step is more careful drug administration. Rapid bolus injections produce significantly more histamine release than do shorter administrations. This finding has been demonstrated for thiopental, propanidid,93 and the Hz-receptor antagonist cimetidine."' Rapid injections should be avoided as much as possible. The practice of administering drugs via the same cannula without flushing can produce precipitates, causing, for example, complement activation via the alternate pathway.lQ3
The above mentioned four measures to prevent reactions involve only single drugs. However, in anesthesia many drugs are used concurrently (e.g., analgesics, hypnotics, muscle relaxants 
Clussijkation of Patients for Whom H ,-t H,-prophylaxis Should Be Recommended
If practitioners do not want to give every surgical patient this prophylaxis, how can patients who are at risk for a more frequent or more severe reaction than are normal patients be defined? The authors cite a number of indications which have been determined by heuristic decision making*l and by using a decision tree ( Figure 2 ). lo5 Prophylaxis with H,-+ H,-receptor antagonists should be used or at least considered:
(1) in patients with a history of adverse drug reactions or history of allergy; (2) in patients who undergo surgery with a high risk of histamine release (transplantation, extracorporeal circulation, bone cement implantation); and (3) in patients >70 years and those with poor physical status (> ASA 3).
Histamine is highly arrhythmogenic. It supports existing arrhythmias and potentiates an increased pulmonary shunt volume, especially in liver cirrhosis." Histamine is more effective in hypovolemic patients. 44 It was the probable cause of death in an 80-year-old woman undergoing bone cement implantation."" Histamine potentiates coagulation. Hence, it is conceivable that elderly patients and those with poor physical states suffer from more severe reactions to histamine than do healthy and fit subjects undergoing elective surgery.
Mode of Administration qf H,-+ H,-prophylaxis Recommended at Present
When H,-+ Hz-prophylaxis is administered, the following conditions for drug administration are used: a slow infusion (about 3-4 minutes) of the H,-+ H,-receptor antagonist dimetindene in a dose of 0.1 mgi kg and the H,-receptor antagonist cimetidine in a dose of 5 mgikg at least 10 minutes before the induction of anesthesia. This protection lasts for more than 2 hours.'1,X0 Less experience is available with ranitidine,4O but a dose of 1.25 mg/kg IV was also found to be effective. 
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